Study identifies EGFR–CDCP1 as co-target pair to enhance tumour killing
Researchers define a proximity-mapping atlas revealing disease-associated membrane spatial communities and identify EGFR–CDCP1 as a co-target pair that enhances tumour killing by multispecific therapeutics.
Headline and summary written by an AI model from the linked article; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The story so far
1 publisher has covered this in 1 article since 9 Sept 2026. Nature published first, on 9 September at 00:00 UTC.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
Sources
Every article we clustered into this story. Headlines link to the publisher.
In this story
- EGFR
- CDCP1